N
TXG icon

Natixis’s 10x Genomics TXG Stock Holding History

Natixis’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-300
Closed -$3.47K – 1232
2025
Q2 		$3.47K Buy
+300
New +$2.73K ﹤0.01% 973
2023
Q2 		– Sell
-1,915
Closed -$107K – 1156
2023
Q1 		$107K Sell
1,915
-120
-6% -$5.6K ﹤0.01% 788
2022
Q4 		$74.2K Buy
+2,035
New +$66.5K ﹤0.01% 896
2022
Q2 		– Sell
-26,537
Closed -$2.02M – 1368
2022
Q1 		$2.02M Sell
26,537
-26,013
-50% -$2.28M 0.01% 749
2021
Q4 		$7.83M Buy
52,550
+11,158
+27% +$1.71M 0.03% 460
2021
Q3 		$6.03M Buy
+41,392
New +$7.11M 0.02% 497
2021
Q2 		– Sell
-46,152
Closed -$8.35M – 1053
2021
Q1 		$8.35M Sell
46,152
-74,854
-62% -$12.9M 0.03% 408
2020
Q4 		$17.1M Buy
+121,006
New +$17.6M 0.06% 285

Other funds holding TXG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Natixis's TXG Position: Q3 2025 in Review

Natixis sold out of 10x Genomics (TXG) in Q3 2025, closing a stake of 300 shares — an estimated $3.47K sold.

Natixis first reported a position in TXG in Q4 2020 and held it in 8 quarters. The position peaked at $17.1M in Q4 2020. 317 funds tracked by Wall St. Rank hold TXG as of Q3 2025.

  • Natixis reported no remaining 10x Genomics position as of Q3 2025 after selling out during the quarter.
  • Natixis sold 300 10x Genomics shares in Q3 2025, an estimated $3.47K.
  • Natixis first reported a position in 10x Genomics in Q4 2020 and held it in 8 quarters.
  • Natixis's 10x Genomics position peaked at $17.1M in Q4 2020.
  • 317 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2025.

Based on Natixis's 13F filing for Q3 2025, filed 14 Nov 2025.